Aegerion Pharmaceuticals, Inc. (AEGR)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.69+0.13 (+8.33%)
At close: 4:00 PM EDT
People also watch:
INFICLVSANACIRWDRPTP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.55
Prev Close1.56
Bid1.71 x 500
Ask1.82 x 500
Day's Range1.53 - 1.70
52wk Range1.23 - 18.29
1y Target EstN/A
Market Cap49.88M
P/E Ratio (ttm)-0.31
Beta0.31
Volume494,603
Avg Vol (3m)678,684
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube12 days ago

    ETF’s with exposure to Aegerion Pharmaceuticals, Inc. : August 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Aegerion Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to AEGR-US. Comparing the performance and risk of Aegerion Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
    Capital Cube13 days ago

    Aegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016

    Categories: Yahoo Finance Click here to see latest analysis Aegerion Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Aegerion Pharmaceuticals, Inc. – Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Esperion Therapeutics, Inc., Ultragenyx Pharmaceutical, Inc., MannKind Corporation and Alnylam ... Read more (Read more...)

  • Aegerion (AEGR) Q2 Loss Wider than Expected, View Intact
    Zacks13 days ago

    Aegerion (AEGR) Q2 Loss Wider than Expected, View Intact

    Aegerion (AEGR) reported a loss of 87 cents per share in the second quarter of 2016, which was wider than the Zacks Consensus Estimate of a loss of 25 cents.